Conference Program
Wednesday, Feb. 8, 2012
7:30 a.m. Registration and Continental Breakfast
8:25 – 8:40 a.m. Welcome
Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX
8:40 - 10:25 a.m. Session I
Moderator: Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX
8:40 - 9:05 — Insights to SUMO-substrate recognition
Christopher D. Lima
Sloan-Kettering Institute, New York, NY
9:05 -9:30 — Phosphorylation-regulated SUMOylation
Xin-Hua Feng
Baylor College of Medicine, Houston, TX
9:30 - 9:55 — Molecular insights into Daxx SUMOylation regulated by phosphorylation and acetylation
Hsui-Ming Shih
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
9:55 - 10:10 — SUMO Signaling Networks Uncovered by Mass Spectrometry
Alfred Vertegaal
Leiden University Medical Center, Leiden, the Netherlands
10:10 – 10:25 — A SNAP-SUMO system for analysis of global SUMOylation changes during keratinocyte differentiation
Van Wilson
Texas A&M Health Science Center, College Station, TX
10:25 - 10:55 a.m. Break
10:55 a.m. – 12:30 p.m. Session II
Moderator: Christopher D. Lima
Sloan-Kettering Institute, New York, NY
10:55 - 11:20 — Regulating cellular activities through SUMO proteases
Mary Dasso
National Institutes of Health, LGRD, NICHD, Bethesda, MD
11:20 - 11:45 — SUMOylation in intestinal homeostasis and cancer
Anne Dejean
Institut Pasteur, Paris, France
11:45 – 12:00 — SUMO-specific Protease 7 regulates heterochromatin protein 1 alpha to promote senescence or epithelial-mesenchymal transition in breast cancer cells
Tasneem Bawa-Khalfe
The University of Texas MD Anderson Cancer Center, Houston, TX
12:00 – 12:15 — Desumoylation in C. elegans epithelial morphogenesis
Limor Broday
Tel Aviv University, Tel Aviv, Israel
12:15 – 12:30 — Characterization of the role of SUMO in the control of protein synthesis in response to stress
Felicity Z. Watts
University of Sussex, Brighton, UK
12:30 a.m. - 1:30 p.m. Lunch
1:30 - 2:55 p.m. Session III
Moderator: Mary Dasso
National Institutes of Health, LGRD, NICHD, Bethesda, MD
1:30 - 1:55 — Regulation of chromatin structure and transcription by SUMO
Grace Gill
Tufts University School of Medicine, Boston, MA
1:55 – 2:10 — A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Brigitte Bressac-de Paillerets
Institut de Cancérologie Gustave Roussy, Villejuif, France
2:10 – 2:25 — Modifying NR5A (SF-1, LRH-1) transcriptional programs by SUMOylation in development and disease
Emily Faivre
University of California San Francisco, San Francisco, CA
2:25 - 2:40 — Examining the role of SUMOylation in the function of a C. elegans T-box transcription factor TBX-2
Paul Huber
University of Illinois at Chicago, Chicago, IL
2:40 - 2:55 — Ubiquitylation of the mineralocorticoid receptor is regulated by aldosterone-induced phosphorylation
Olivier Staub
University of Lausanne, Lausanne, Switzerland
2:55 - 3:25 p.m. Break
3:25 - 5:00 p.m. Session IV
Moderator: Grace Gill
Tufts University School of Medicine, Boston, MA
3:25 - 3:50 — SUMOylation in cardiac development and disease
Robert Schwartz
University of Houston, Houston, TX
3:50 - 4:05 — SUMO1-dependent regulation of SR calcium ATPase Pump, SERCA2a in heart failure
Changwon Kho
Mount Sinai School of Medicine, New York, NY
4:05 – 4:30 — SENP3: Links oxidation and ubiquitination with SUMOylation
Jing Yi
Shanghai Jiao Tong University School of Medicine, Shanghai, China
4:30 - 4:45 — PML Nuclear Bodies: a ROS-induced shell of cross-linked PML for SUMOylation/degradation control
Valérie Lallemand-Breitenbach
Institut Universitaire Hématologie, Université Paris Diderot, Paris, France
4:45 – 5:00 — C-terminal domain SUMOylation of DNA Topoisomerase IIα recruits checkpoint complex on centromeres
Yoshiako Azuma
University of Kansas, Lawrence, KS
5:15 – 8:15 p.m. Session V
Poster Session, Reception and Dinner
5:15 - 6:45 — Poster Session, Even Side, and Reception
6:15 - 7:15 — Dinner Buffet
6:45 - 8:15 — Poster Session, Odd Side
Thursday, Feb. 9, 2012
7:30 a.m. Registration and Continental Breakfast
8:30 - 10:20 a.m. Session VI
Moderator: Ze'ev Ronai
The Burnham Institute, La Jolla, CA
8:30 – 9:00 — Challenging the polyubiquitin degradation signal: The proteasome can do with less
Aaron Ciechanover
Technion-Israel Institute of Technology, Haifa, Israel
9:00 – 9:25 — Mechanisms of proteasome assembly, activation, and function
George N. DeMartino
The University of Texas Southwestern Medical Center, Dallas, TX
9:25 – 9:50 — Regulating mitochondrial dynamics by the ubiquitin-proteasome system
Allan Weissman
National Cancer Institute, Frederick, MD
9:50 – 10:05 — Epsin-ENTH domain is a bona fide ubiquitin binding domain
Gali Prag
Tel Aviv University, Tel Aviv, Israel
10:05 – 10:20 — Int6 impacts breast cancer by regulating both proteasomal degradation and translation initiation
Eric Chang
Baylor College of Medicine, Houston, TX
10:20 – 10:50 a.m. Break
10:50 a.m. – 12:45 p.m. Session VII
Moderator: Avram Hershko
Technion-Israel Institute of Technology, Haifa, Israel
10:50 - 11:15 — Mechanisms of SCF-mediated regulation of NF-κB2 and BCL6: relevance in B-cell neoplasms
Michele Pagano
New York University School of Medicine, New York, NY
11:15 – 11:40 — Siah2 in hypoxia and cancer
Ze'ev Ronai
The Burnham Institute, La Jolla, CA
11:40 – 12:05 — Non-canonical regulation of gene expression via hypoxia-inducible factor
Michael Ohh
University of Toronto, Toronto, ON, Canada
12:05 – 12:30 — Pc2contributes to pathogenesis of hepatocellular carcinoma via SUMOylating HIF-1α and inducing angiogenesis
Guo-Qiang Chen
Shanghai Jiao Tong University School of Medicine, Shanghai, China
12:30 – 12:45 — KLHL20 mediates PML ubiquitination to potentiate HIF-1 signaling and prostate cancer progression
Ruey-Hwa Chen
Institute of Biomedical Chemistry, Academia Sinica, Taipei, Taiwan
12:45 – 1:45 p.m. Lunch
1:45 – 3:35 p.m. Session VIII
Moderator: Aaron Ciechanover
Technion-Israel Institute of Technology, Haifa, Israel
1:45 – 2:10 — Ubl protein activating enzymes
Neil Bence
Millennium: The Takeda Oncology Company, Cambridge, MA
2:10 – 2:35 — Targeting SUMOylation for the development of research tools and therapeutics
Yuan Chen
Beckman Research Institute of the City of Hope, Duarte, CA
2:35 – 2:50 — Small-molecule inhibitors of de-ubiquitinating enzymes for cancer treatment
Martina Bazzaro
University of Minnesota Twin Cities, Minneapolis, Minnesota
2:50 – 3:05 — Novel selective inhibitor of POSH for the potential treatment of cancer and inflammatory diseases
Ety Klinger
Proteologics LTD, Rehovot, Israel
3:05 – 3:20 — Artificial SUMO Ligases - An innovative tool to study the effects of SUMOylation on specific targets
German Rosas-Acosta
The University of Texas at El Paso, El Paso, TX
3:20 – 3:35 — Development of small molecules that induce IAP-mediated ubiquitylation and proteasomal degradation
Mikihiko Naito
National Institute of Health Sciences, Tokyo, Japan
3:35 – 4:05 p.m. Break
4:05 – 5:40 p.m. Session IX
Moderator: Allan Weissman
National Cancer Institute, Frederick, MD
4:05 – 4:30 — Ubiquitin signaling in the RIG-I anti-viral innate immunity pathway
Zhijian 'James' Chen
University of Texas Southwestern Medical Center, Dallas, TX
4:30 – 4:55 — SENP1 and interferon-γ signaling
Jinke Cheng
Shanghai Jiao Tong University School of Medicine, Shanghai, China
4:55 – 5:10 — SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation
Thang Nguyen
The University of Texas MD Anderson Cancer Center, Houston, TX
5:10 – 5:25 — Inactivation of USP18 isopeptidase function enhances ISGylation and antiviral activity in vivo
Klaus-Peter Knobeloch
University Freiburg, Freiburg, Germany
5:25 – 5:40 — PML and PMLRARα interact with Fas to regulate Fas-mediated apoptosis in vivo
Felipe Samaniego
The University of Texas MD Anderson Cancer Center, Houston, TX
Friday, Feb. 10, 2012
7:30 a.m. Registration and Continental Breakfast
8:30 – 8:40 — Welcome Remarks
Ronald DePinho, President
The University of Texas MD Anderson Cancer Center, Houston, TX
8:40 - 10:30 a.m. Session X
Moderator: Michele Pagano
New York University School of Medicine, New York, NY
8:40 – 9:10 — Regulation of APC/C ubiquitin ligase in the cell cycle
Avram Hershko
Technion-Israel Institute of Technology, Haifa, Israel
9:10 – 9:35 — Identification of Cullin Ring ligase substrates
Steve Elledge
Harvard Medical School, Boston, MA
9:35 – 10:00 — Metabolic regulation by ubiquitin ligases
Cam Patterson
The University of North Carolina at Chapel Hill, Chapel Hill, NC
10:00 – 10:15 — The glomuvenous malformation protein glomulin binds Rbx1 and regulates CRL-mediated turnover of Fbw7
James DeCaprio
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
10:15 – 10:30 — Distinct E3 ligases regulate Akt ubiquitination, activation and cancer development
Hui-Kuan Lin
The University of Texas MD Anderson Cancer Center, Houston, TX
10:30 – 11:00 a.m. Break
11:00 a.m. – 12:25 p.m. Session XI
Moderator: Alan D’Andrea
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
11:00 – 11:25 — Crosstalk between the ubiquitin and SUMO pathways
Tony Hunter
Salk Institute for Biological Studies , La Jolla, CA
11:25 – 11:40 — Targeting SUMOylation for degradation during DNA damage response
David Ann
Beckman Research Institute of the City of Hope, Duarte, CA
11:40 – 11:55 — The role of SUMO targeted ubiquitin ligase in transcriptional activation
Amir Orian
Technion-Israel Institute of Technology, Haifa, Israel
11:55 – 12:10 — RNF4 regulates BLM in replication-fork stability
Nathan Ellis
University of Illinois at Chicago, Chicago, IL
12:10 – 12:25 — HSP27 selectively targets ΔF508 CFTR for degradation via the SUMO pathway
Raymond Frizzell
University of Pittsburgh, Pittsburgh, PA
12:25 – 1:25 p.m. Lunch
1:25 – 3:10 p.m. Session XII
Moderator: Tony Hunter
Salk Institute for Biological Studies, La Jolla, CA
1:25 – 1:50 — Regulation of the Fanconi anemia pathway by ubiquitin and SUMO
Alan D’Andrea
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1:50 – 2:15 — RNF4 STUbL in the DNA damage response
Yaron Galanty
The Gurdon Institute, University of Cambridge, Cambridge, UK
2:15 – 2:40 — The role of SUMOylation in DNA repair and replication stress response pathways
Michael Matunis
Johns Hopkins University, Baltimore, MD
2:40 – 2:55 — SENP6 in DNA replication and repair
Hong Dou
The University of Texas MD Anderson Cancer Center, Houston, TX
2:55 – 3:10 — USP28 is a modulator of the Fanconi anemia pathway and DNA double-strand break repair
Celine Jacquemont
Fred Hutchinson Cancer Research Center, Seattle, WA
3:10 – 3:40 p.m. Break
3:40 – 5:10 p.m. Session XIII
Moderator: George DeMartino
The University of Texas Southwestern Medical Center, Dallas, TX
3:40 – 3:55 — SUMOylation of the α-kleisin subunit of cohesin is necessary for DNA damage-induced cohesion
Luis Aragon
MRC Clinican Sciences Centre, Imperial College, London, UK
3:55 – 4:10 Chromatin remodeling-assisted ubiquitylation
Nico Dantuma
Karolinska Institutet, Stockholm, Sweden
4:10 – 4:25 —Roles of COP9 signalosome in cancer
Mong-Hong Lee
The University of Texas MD Anderson Cancer Center, Houston, TX
4:25 – 4:40 — DEN1 and COP9 signalosome interaction balances cellular deneddylase activity with developmental functions
Gerhard Braus
Institute of Microbiology and Genetics, Goettingen, Germany
4:40 – 4:55 — Expression of COP9 signalosome subunits is coordinated by miRNAs: Relevance for tumor therapy
Wolfgang Dubiel
Universitätsmedizin Berlin, Berlin, Germany
4:55 – 5:10 — COP9 signalosome and deubiquitinylases control NF-kB/RelA transcriptional activity
Michael Naumann
Otto von Guericke University, Magdeburg, Germany
5:10 – 5:30 p.m. Break
5:30 – 8:30 p.m. Session XIV
Poster Session, Reception and Dinner
5:30 - 7:00 — Poster Session, Even Side, and Reception
6:30 - 7:30 — Dinner Buffet
7:00 - 8:30 — Poster Session, Odd Side
Saturday, Feb. 11, 2012
7:30 a.m. Continental Breakfast
8:30 - 10:00 a.m. Session XV
Moderator: Cam Patterson
The University of North Carolina at Chapel Hill, Chapel Hill, NC
8:30 – 8:55 —Ubiquitin ligases involved in muscle atrophy and protection against neurodegeneration.
Alfred Goldberg
Harvard Medical School, Boston MA
8:55 – 9:20 — The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling
David Glass
Novartis Institutes for BioMedical Research Inc., Cambridge, MA
9:20 – 9:45 — Chaperone-mediated protein degradation as a modulator of gene expression.
Henry Epstein
University of Texas Medical Branch at Galveston, Galveston, TX
9:45 – 10:00 — Sphingosine-1-phosphate: A cofactor for E3 ubiquitin ligases
Sarah Spiegel
Virginia Commonwealth University School of Medicine, Richmond, VA
10:00 –10:20 a.m. Break
10:20 a.m. – 12:00 noon Session XVI
Moderator: Michael Matunis
Johns Hopkins University, Baltimore, MD
10:20 – 10:45 — SUMO and sudden death
Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX
10:45 – 11:00 — MeCP2 interacting partners in development and Rett Syndrome
Mary E. Donohoe
Weill Cornell Medical College, White Plains, NY
11:00 – 11:15 — SUMO1 transgenic mouse models and neurodegenerative disease
Paul Fraser
University of Toronto, Toronto, ON, Canada
11:15 – 11:30 — Massive activation of the SUMO conjugation pathway in human brain tumors; implications for new therapeutic strategies
Wulf Paschen
Duke University Medical Center, Durham, NC
11:30 – 11:45 — Deconstructing how neurons react to ATP deficits: Ubiquitination, proteasomes, IDPs & nannies
Maria E. Figueiredo-Pereira
Hunter College, City University of New York, New York, NY
11:45 – 12:00 — INNO-406, a second generation Abl-inhibitor, as a Parkinson’s disease therapy
Syed Imam
US FDA/National Center for Toxicological Research, Jefferson, AZ
Closing Comments and Adjourn
Edward T.H. Yeh
The University of Texas
Box lunch pickup

